Sitemap
May 30, 2009 Articles
Filter by Available Specialty
- 5-FU, mitomycin-C confirmed as standard of care in anal cancer
- ATLAS: Adding erlotinib to bevacizumab for maintenance therapy improved PFS in NSCLC
- NSABP C-08: Bevacizumab plus standard therapy failed to improve DFS in early-stage colon cancer
- SYMMETRY halted early; elesclomol/paclitaxel fails to increase PFS for metastatic melanoma